MBM-55S

• UNSPSC Description:

  MBM-55S is a potent NIMA-related kinase 2 (Nek2) inhibitor with an IC50 of 1 nM. MBM-55S shows a 20-fold or greater selectivity in most kinases with the exception of RSK1 (IC50=5.4 nM) and DYRK1a (IC50=6.5 nM). MBM-55S effectively inhibits the proliferation of cancer cells by inducing cell cycle arrest and apoptosis. MBM-55S shows antitumor activities, and no obvious toxicity to mice[1].

• Target Antigen:

  Apoptosis; DYRK; NEKs; Ribosomal S6 Kinase (RSK)

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Cell Cycle/DNA Damage;MAPK/ERK Pathway;Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/mbm-55s.html

• Solubility:

  10 mM in DMSO

• Smiles:

  NC(C(C=C1)=C(OCC2=CC=CC(F)=C2)C=C1C3=CN=C4N3C=CC(C5=CN(CCN(C)C)N=C5)=C4)=O.O=C(O)CCC(O)=O.O=C(O)CCC(O)=O

• Molecular Weight:

  734.73

• References & Citations:

  [1]Xi JB, et al. Structure-based design and synthesis of imidazo[1,2-a]pyridine derivatives as novel and potent Nek2 inhibitors with in vitro and in vivo antitumor activities. Eur J Med Chem. 2017 Jan 27;126:1083-1106.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2083624-07-9